D1 Capital Partners led the latest financing round totaling $30 million for Silicon Valley medical device company Sight Sciences.
Proceeds from the Series E Preferred Stock financing round will be used for continued clinical and operational development and to support commercial expansion for Sight Sciences OMNI and TearCare products catering to eye disease treatment.
“In minimally invasive glaucoma surgery the safety, efficacy and versatility of the OMNI device is unmatched,” said James Rogers, analyst at D1 Capital Partners. “Additionally, we feel the early success with the commercialization of TearCare suggests this innovative and effective solution . . .
Continue Reading With Our Special Offer
Unlock this article instantly, along with the rest of our premium content and newsletters, with a 20% discount by using the coupon code VIDRIO2021.
Already a subscriber? Log in.